So it’s taken Starpharma 23 years as a listed entity to finally get to the pointy end of their drug development goal. That is, to get 3 internal DEP cancer drugs to the point of proof of concept before potentially licencing out.
Yet here we are with proof of concept, but with a share price of 15 cents which is a smidgin above record lows, and there appears no deal in sight despite Starpharma utterances for over 5 years that they are in constant dialogue with potential partners.
Has the market spoken? What are the expectations for the year ahead? Will we see 10 cents by year end, or can Cheryl pull a rabbit out of the manky and smelly hat that is tucked away in the HQ storeroom?
And to think that another poster who is a significant shareholder in Starpharma tried to drum up unbridled excitement on this public forum by predicting the SPL share price would increase by 400% in the 2 weeks prior to end of 2023. Is that even ethical?
I’m afraid it doesn’t look like the worm has turned at all, but more like the worm has been burned.
Thoughts….?
Yours sincerely Sarge
SPL Price at posting:
15.0¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)